Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) – Investment analysts at Jefferies Group issued their FY2022 earnings estimates for Zynerba Pharmaceuticals in a research report issued to clients and investors on Monday. Jefferies Group analyst B. Amin expects that the company will earn $0.06 per share for the year.
Several other equities research analysts have also commented on ZYNE. Piper Jaffray Companies upped their price target on shares of Zynerba Pharmaceuticals from $16.00 to $20.00 in a report on Tuesday, November 14th. Oppenheimer reaffirmed a “hold” rating on shares of Zynerba Pharmaceuticals in a report on Tuesday, November 14th. Zacks Investment Research lowered shares of Zynerba Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, November 18th. Cantor Fitzgerald set a $17.00 target price on shares of Zynerba Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, November 20th. Finally, Canaccord Genuity set a $18.00 target price on shares of Zynerba Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, December 4th. One research analyst has rated the stock with a sell rating, six have given a hold rating and seven have assigned a buy rating to the stock. Zynerba Pharmaceuticals has an average rating of “Hold” and an average target price of $17.77.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) last posted its quarterly earnings results on Monday, March 12th. The company reported ($0.60) EPS for the quarter, meeting the consensus estimate of ($0.60). During the same quarter in the previous year, the business earned ($0.71) earnings per share.
In other news, major shareholder Michael Rapp bought 15,000 shares of the stock in a transaction dated Tuesday, January 2nd. The shares were acquired at an average cost of $12.99 per share, with a total value of $194,850.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 9.91% of the company’s stock.
Hedge funds have recently bought and sold shares of the company. Engineers Gate Manager LP purchased a new stake in shares of Zynerba Pharmaceuticals during the 3rd quarter worth about $263,000. Teachers Advisors LLC acquired a new position in shares of Zynerba Pharmaceuticals during the 2nd quarter worth about $341,000. Perceptive Advisors LLC raised its position in shares of Zynerba Pharmaceuticals by 230.7% during the 3rd quarter. Perceptive Advisors LLC now owns 130,700 shares of the company’s stock worth $1,320,000 after purchasing an additional 230,700 shares during the last quarter. Granite Point Capital Management L.P. raised its position in shares of Zynerba Pharmaceuticals by 47.9% during the 3rd quarter. Granite Point Capital Management L.P. now owns 200,000 shares of the company’s stock worth $1,672,000 after purchasing an additional 64,800 shares during the last quarter. Finally, Wells Fargo & Company MN raised its position in shares of Zynerba Pharmaceuticals by 3,759.5% during the 3rd quarter. Wells Fargo & Company MN now owns 34,079 shares of the company’s stock worth $285,000 after purchasing an additional 33,196 shares during the last quarter. 29.07% of the stock is currently owned by institutional investors and hedge funds.
Zynerba Pharmaceuticals Company Profile
Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.
Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.